Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
51.61 50.6 50.97 50.8 50.43 Last
24203870 20678590 19765200 13902400 19346950 Volume
+0.21% -1.96% +0.73% -0.33% -0.73% Change
Estimated financial data (e)
Sales 2021 37 550 M 5 836 M 5 836 M
Net income 2021 4 674 M 726 M 726 M
Net Debt 2021 17 898 M 2 782 M 2 782 M
P/E ratio 2021 27,2x
Yield 2021 1,01%
Sales 2022 43 540 M 6 767 M 6 767 M
Net income 2022 6 259 M 973 M 973 M
Net Debt 2022 16 166 M 2 513 M 2 513 M
P/E ratio 2022 21,3x
Yield 2022 1,42%
Capitalization 119 B 18 446 M 18 448 M
EV / Sales 2021 3,64x
EV / Sales 2022 3,10x
Nbr of Employees 34 375
Free-Float 58,7%
More Financials
Company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Ratings of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
10/14SHANGHAI FOSUN PHARMACEUTICAL : Date of board meeting(h shares)
PU
10/13SHANGHAI FOSUN PHARMACEUTICAL : Helsinn and Fosun Pharma sign exclusive license and distri..
AQ
10/12SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Setting Up Children-Focused Medical Services ..
MT
10/11SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction - formation of joint venture (h shar..
PU
10/11Fosun Health Enters Joint Venture Agreement with Forte Industrial Development
CI
10/07SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
10/01SHANGHAI FOSUN PHARMACEUTICAL : Asian Private Equity Firm CBC to Buy 43% Stake in Yaneng B..
MT
09/30SHANGHAI FOSUN PHARMACEUTICAL : Discloseable transaction - disposal of equity interest in ..
PU
09/30C-Bridge Healthcare Fund V, L.P., a fund of C-Bridge Capital Investment Management, Ltd..
CI
09/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Raises Nearly $186 Million from Sale of Renmi..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins US FDA Nod to Start Clinical Trial of Ex..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - on completion of the issuance of ..
PU
09/10SHANGHAI FOSUN PHARMACEUTICAL : Proposed adoption of rsu scheme by a subsidiary (h ..
PU
09/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
More news
News in other languages on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
10/12Fosun Pharma crée une coentreprise de services médicaux destinés aux enfants dans une v..
10/01La société asiatique de capital-investissement CBC rachète 43 % des parts de Yaneng Bio..
09/22Fosun Pharma lève près de 186 millions de dollars grâce à la vente d'obligations en ren..
09/21Fosun Pharma obtient le feu vert de la FDA pour lancer l'essai clinique d'un traitement..
09/01Fosun Pharma obtient 100 millions de dollars supplémentaires pour la production du vacc..
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 50,43 CNY
Average target price 68,40 CNY
Spread / Average Target 35,6%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman